EGFR and colorectal carcinoma: As far as targeted drugs, cetuximab [2] and panitumumab [3] target the epidermal growth factor receptor (EGFR) and benefit CRC patients with EGFR overexpression, but they are ineffective in patients without EGFR expression [4, 5].